XENCOR INC

Insider buying spree at Xencor signals executive confidence in upcoming biotech catalysts—investors see bullish potential amid 44% monthly gains.

Insider sales at Xencor were a planned, compensation‑driven move, not a red flag, with robust fundamentals and a steady growth outlook.

Insider buying at Xencor signals confidence amid volatility—VP CSO purchases 24k shares, boosting buzz and hinting at a near‑term rally.